Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Invesco Ltd.

Invesco Ltd. boosted its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 173.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 449,180 shares of the company's stock after buying an additional 285,156 shares during the quarter. Invesco Ltd. owned approximately 0.79% of Harmony Biosciences worth $15,456,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of Harmony Biosciences by 1.9% in the 4th quarter. FMR LLC now owns 5,329,902 shares of the company's stock valued at $183,402,000 after buying an additional 101,182 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Harmony Biosciences by 36.4% during the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after acquiring an additional 1,262,362 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Harmony Biosciences by 18.2% in the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after purchasing an additional 351,582 shares during the last quarter. American Century Companies Inc. boosted its stake in Harmony Biosciences by 28.7% in the 4th quarter. American Century Companies Inc. now owns 1,102,604 shares of the company's stock worth $37,941,000 after purchasing an additional 246,140 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Harmony Biosciences by 22.8% during the 4th quarter. Geode Capital Management LLC now owns 902,934 shares of the company's stock worth $31,077,000 after purchasing an additional 167,516 shares during the last quarter. Institutional investors own 86.23% of the company's stock.

Insider Buying and Selling

In other news, CFO Sandip Kapadia sold 1,775 shares of the company's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $38.05, for a total value of $67,538.75. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jeffrey Dierks sold 1,629 shares of Harmony Biosciences stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $38.02, for a total transaction of $61,934.58. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,529 shares of company stock worth $619,167. 23.60% of the stock is owned by insiders.

Harmony Biosciences Price Performance

NASDAQ HRMY traded up $0.46 on Thursday, hitting $29.36. The company had a trading volume of 231,364 shares, compared to its average volume of 674,625. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The company's fifty day moving average price is $32.34 and its 200-day moving average price is $34.33. The company has a market capitalization of $1.68 billion, a PE ratio of 13.91, a PEG ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. The business had revenue of $201.30 million during the quarter, compared to analysts' expectations of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business's revenue was up 19.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 earnings per share. As a group, analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on HRMY shares. HC Wainwright reiterated a "buy" rating and set a $70.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Needham & Company LLC restated a "buy" rating and set a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Mizuho raised their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a report on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price target on the stock. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $53.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.